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A B S T R A C T
Background
Globally, about five per cent of children are born with congenital or genetic disorders. Themost common autosomal recessive conditions
are thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease, with higher carrier rates in specific patient populations.
Identifying and counselling couples at genetic risk of the conditions before pregnancy enables them tomake fully informed reproductive
decisions, with some of these choices not being available if genetic counselling is only offered in an antenatal setting.
Objectives
To assess the effectiveness of systematic preconception genetic risk assessment to improve reproductive outcomes in women and their
partners who are identified as carriers of thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease in healthcare settings when
compared to usual care.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Trials Registers. In addition, we searched for all relevant
trials from 1970 (or the date at which the database was first available if after 1970) to date using electronic databases (MEDLINE,
Embase, CINAHL, PsycINFO), clinical trial databases (National Institutes of Health, Clinical Trials Search portal of theWorld Health
Organization, metaRegister of controlled clinical trials), and hand searching of key journals and conference abstract books from 1998
to date (European Journal of Human Genetics, Genetics in Medicine, Journal of Community Genetics). We also searched the reference lists
of relevant articles, reviews and guidelines and also contacted subject experts in the field to request any unpublished or other published
trials.
Date of latest search of the registers: 25 June 2015.
Date of latest search of all other sources: 10 December 2014.
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Selection criteria
Any randomised or quasi-randomised control trials (published or unpublished) comparing reproductive outcomes of systematic pre-
conception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease when compared to usual
care.
Data collection and analysis
We identified 19 papers, describing 13 unique trials whichwere potentially eligible for inclusion in the review.However, after assessment,
no randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-
Sachs disease were found.
Main results
No randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-
Sachs disease were found.
Authors’ conclusions
As no randomised controlled trials of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-
Sachs disease were found for inclusion in this review, the research evidence for current policy recommendations is limited to non-
randomised studies.
Information from well-designed, adequately powered, randomised trials is desirable in order to make more robust recommendations
for practice. However, such trials must also consider the legal, ethical, and cultural barriers to implementation of preconception genetic
risk assessment.
P L A I N L A N G U A G E S U M M A R Y
Identifying carrier status for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease in non-pregnant women and
their partners
Review question
We looked for evidence to show whether identifying people who are carriers for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-
Sachs disease, before pregnancy leads to improving reproductive choice and pregnancy outcomes.
Background
Across the world, about five per cent of children are born with genetic disorders. These disorders can be passed down from parent to
child. There are tests to identify the genetic risk of the most common genetic disorders (thalassaemia, sickle cell disease, cystic fibrosis,
or Tay-Sachs disease) before pregnancy. In these disorders, called autosomal recessive conditions, the parents of affected children are
’carriers’ of the condition, which means they do not usually have symptoms. All ’carrier’ couples will have a 25 per cent chance of having
an affected child. Risk assessment for these genetic disorders prior to pregnancy would benefit potential parents who may be carriers.
This information would give the at-risk couple the opportunity to make fully informed decisions about family planning. However,
genetic risk assessment before pregnancy may potentially have a negative psychological impact.
Search date
We last looked for evidence on 10 December 2014.
Study characteristics
We did not find any trials that we could include in this review.
Key results
Although no trials were identified in which volunteers would have equal chances of being in either group, there are several studies which
are not so strictly designed which support current policy recommendations for genetic risk assessment prior to pregnancy in routine
clinical practice. Any future trials need to consider legal, ethical and cultural barriers to implementation.
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B A C K G R O U N D
A glossary of terms is available as an appendix (Appendix 1).
Description of the condition
Genetic medicine is expanding into almost every aspect of health
care; reproductive risk assessment during the preconception pe-
riod is a prime example. Identifying genetic risks before pregnancy
or conception might produce significant benefits, such as provid-
ing information about the risk of having children with genetic
conditions and thus giving couples or prospective parents the op-
portunity to make more informed reproductive decisions. It has
been estimated that a couple has a baseline risk of two to three per
cent of having a child with a congenital or genetic disorder (Teeuw
2010). The probability of having an affected child increases when
there is a family history of genetic disorders (Shapira 2006; Teeuw
2010). Globally, about five per cent of children are born with con-
genital or genetic disorders (WHO 1999).
Preconception risk assessment for autosomal recessive genetic dis-
orders would benefit couples who may be carriers. The most com-
mon examples of these autosomal recessive disorders are thalas-
saemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. In
these disorders, such carriers are usually asymptomatic; however,
their child will be affected if he or she inherits the affected genes
from both parents. All carrier couples have a 25 per cent chance
of having an affected child. These conditions have a high mor-
bidity risk, are potentially life-threatening and have a significant
psychological impact not only on the affected child, but also on
their families or care givers. These diseases are also more prevalent
in individuals of particular ethnic backgrounds (WHO 2000).
The need for medical care, as well as psychological interventions
to offer behavioural and emotional support, imposes a potentially
high economic and public health burden. In view of the magni-
tude of these conditions and their implications, there have been
considerable efforts to identify the genetic reproductive risk for
the four specified conditions and offer support to potential par-
ents before the birth of an affected child. Women and couples
at increased genetic risk, as well as healthcare professionals, have
recognised the importance of preconception assessment (Boulton
1996; Henneman 2001; Locock 2008; Mennie 1998; Poppelaars
2004; Watson 1999; Wille 2004). To date, the practical experi-
ence of reproductive genetic risk assessment for autosomal reces-
sive disorders focuses mainly on the antenatal and newborn period
(Qureshi 2004). Identifying genetic reproductive risk during the
antenatal period leaves the couple a short period of time to make
difficult or limited choices, such as terminating the pregnancy or
continuing with the pregnancy and caring for the affected child
(Dormandy 2008). Identifying couples who have confirmed ge-
netic carrier status before conception provides an opportunity for
individuals or couples tomake fully informed reproductive choices
including avoiding pregnancy, pre-implantation diagnosis and in
vitro fertilization, arranging early prenatal diagnosis and antenatal
care and also considering adoption of a child (Jones 2002; Wille
2004).
Thalassaemia
According to the WHO, every year 300,000 infants are born
with major haemoglobin disorders, the most common being tha-
lassaemia and sickle cell disease (WHO 1999). Thalassaemia is
characterised by the defects or absence of synthesis in one of the
two globin chains (α or β) which form the normal adult human
haemoglobin molecule; this leads to haemolytic anaemia (Peters
2012). Thalassaemia can be diagnosed by measuring fractions of
haemoglobin A and haemoglobin F with high performance liquid
chromatography (HPLC) or electrophoresis. In addition, DNA
analysis is required to detect an α or β globin chain mutation
(Peters 2012). It is estimated that between two and five per cent
of the world’s population are carriers and this is more prevalent
in the Mediterranean and Southern Asian populations (Modell
2001).Morbidity is related to severe anaemia and an affected child
will require lifelong blood transfusions. Multiple blood transfu-
sions may eventually result in iron overload and potentially cause
heart failure, infection, hypogonadism, infertility, diabetes mel-
litus, and hypothyroidism. Affected individuals may die prema-
turely, unless given optimal medical management. In individuals
with thalassaemia and their families or care givers, psychosocial
problems have also been reported, for example stigmatisation, iso-
lation, family adjustment, coping with school and education, and
social interaction (Gharaibeh 2009; Ratip 1996; Telfer 2005).
Sickle cell disease
Sickle cell disease is caused by a mutation in the haemoglobin
gene (βS ) which individuals inherit from both parents (Weatherall
1997). TheWHO estimates that sickle cell disease affects 275,000
conceptions each year globally (Modell 2008; Yusuf 2011). Diag-
nosis is confirmed using HPLC or electrophoresis with the detec-
tion of haemoglobin S and C fraction. It affects mainly individuals
of African origin, but is also found in Indian and some Mediter-
ranean populations. The reported prevalence of carrier frequency
ranges from one to 40 per cent, depending on the population
group. The condition causes the red blood cells to have a sickle
shape which results in premature haemolysis, and can lead to life-
threatening acute and chronic vaso-occlusion, including renal and
cardiovascular complications. Individuals with this condition are
also susceptible to serious septicaemia. Like thalassaemia, individ-
uals and their families are also confronted with psychosocial chal-
lenges which include the disruption of school and work, social
isolation and loneliness, stigmatisation, bullying, and rejection by
peers (Barbarin 1999).
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Cystic fibrosis
Cystic fibrosis is caused by a mutation in the gene cystic fibrosis
transmembrane conductance regulator (CFTR); more than 1500
CFTR mutations have now been identified. Diagnosis of cystic fi-
brosis is indicated by phenotypic features (chronic sino-pulmonary
disease, gastrointestinal and nutritional abnormalities, obstructive
azoospermia and salt-loss syndromes), a family history of cystic
fibrosis or a positive newborn screening test, together with labora-
tory evidence of a CFTR abnormality. Abnormalities in the CFTR
can be identified by elevated sweat chloride concentrations (sweat
test), identification of twoCFTRmutations, or in vivo demonstra-
tion of characteristic abnormalities in ion transport across the nasal
epithelium. Carriers are confirmed by identification of a CFTR
mutation from the blood or saliva (CDC 2004).
Cystic fibrosis ismost common among people of European descent
with a carrier frequency of 1 in 25 (Murray 1999). This condi-
tion is commonly associated with recurrent pulmonary infections,
which potentially lead to bronchiectasis and atelectasis, and also
pancreatic exocrine insufficiency. There is currently no cure for
the disease, with treatment mainly aimed at improving a person’s
quality of life. The need for emotional and social adjustment is a
significant psychosocial consequence for people with cystic fibrosis
(Bregnballe 2007; Glasscoe 2008). In addition, poor adherence to
treatment has also been reported due to the burden of treatment
and the long-term management of the condition (Abbot 1996).
Tay-Sachs disease
Tay-Sachs disease is caused by a genetic mutation in the α chains
of the hexosaminidase A (Hex A) isozyme in the gangliosides in
nerve cells of the brain (Bach 2001). The disease is diagnosed by
measuring the activity of hexosaminidase A and further identifica-
tion of a genetic mutation in Hex A (ACOGCommittee Opinion
2005). It is most prevalent in the Ashkenazi Jewish and French
Canadian populations, with a carrier frequency of around 1 in 30
(Petersen 1983; Palomaki 1995). The condition leads to a pro-
gressive deterioration of mental and physical abilities. Death usu-
ally occurs before five years of age. At present, there is no cure or
available treatment.
Description of the intervention
Women and their partners can be assessed during the preconcep-
tion period to identify if they are carriers of one of these four au-
tosomal recessive conditions. These four conditions represent the
most common autosomal recessive conditions globally. Cystic fi-
brosis is most common in Northern European populations; sickle
cell disease and thalassaemia are most common non-Northern Eu-
ropean populations, and Tay-Sachs disease is most common in in-
dividuals of Ashkenazi Jewish and French Canadian ancestry. Ap-
proaches to improve health outcomes and reproductive choice in
couples who carry these genetic conditions should be generalizable
to other, but rarer, autosomal recessive conditions. In populations
with high carrier rates or significant burden of affected individuals,
or both, carrier screening may be offered during preconception
to all women in some healthcare settings (PFASP England 2013).
More commonly, women and their partners may be assessed on
the need for carrier testing. This assessment would be based firstly
on a review of the family history for any of the autosomal reces-
sive conditions or their carrier status; and, secondly, on the ethnic
origin of the woman and her partner (Dyson 2006). This assess-
ment of ancestry will identify if the individual originates from an
ethnic group with a greater probability of being a healthy carrier
of any of the four autosomal recessive disorders; for example those
with Ashkenazi Jewish ancestry are more likely to carry Tay-Sachs
disease, whilst those of African descent may carry sickle cell trait.
The benefits of recording family history as one of the components
of preconception health checks have been reported in previous
observational community-based studies for a broad range of ge-
netic conditions in both the United Kingdom (Rose 1999) and
Hungary (Czeizel 2012).
Overall, previous interventions have involved genetic carrier test-
ing or screening (with or without educational support and ge-
netic counselling) or both. There is often confusion between the
terms genetic carrier testing and screening (Nuffield Council on
Bioethics 1993). Genetic carrier testing refers to the testing of
individuals to determine the presence or absence of the carrier
status (Human Genetics Commission 2011). This testing could,
for example, be in the context of a family history of the autoso-
mal recessive condition or relevant ethnicity. On the other hand,
genetic carrier screening involves offering or testing the whole
population group irrespective of individual risk (Castellani 2010;
Human Genetics Commission 2011). Both genetic carrier testing
and screening involves the analysis of blood, tissue or bodily fluid
samples.
With regards to the actual genetic carrier tests, currently either
HPLC or electrophoresis is used to detect haemoglobin variants
and to confirm carrier status for thalassaemia and sickle cell dis-
ease (NHS Screening Programme 2013). Carrier status for cys-
tic fibrosis is confirmed by analysing the mutations in the gene
CFTR, using DNA commonly obtained from white blood cells,
mouthwashes and buccal swabs (Murray 1999). Confirmation of
Tay-Sachs disease carrier status comprises of molecular analysis to
detect genetic mutations in the α chains of the hexosaminidase
A (Hex A) isozyme (ACOG Committee Opinion 2005). To im-
prove detection rate, this should be combined with biochemical
tests (ACOG Committee Opinion 2005).
For each condition, as well as confirmed carrier status identi-
fied by genetic carrier tests, there are other laboratory investiga-
tions that could indicate a probable carrier state. A microcytic or
hypochromic blood picture, or both, without anaemia suggests a
probable thalassaemia carrier, whilst a probable sickle cell carrier is
indicated by a positive sickle solubility test. Elevated sodium chlo-
ride levels in sweat can indicate a probable cystic fibrosis carrier
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state.
At present, there is no formal or standard recommendation
that fully addresses preconception genetic risk assessment (NHS
Screening Programme 2013). There is variability in how precon-
ception genetic risk assessment is offered across countries. For ex-
ample, in Iran, screening for haemoglobinopathies is offered in
pre-marital clinics (Samavat 2004), whereas in the United King-
dom, screening for any reproductive genetic disorder may be of-
fered opportunistically in a range of settings such as family plan-
ning clinics (Watson 1999). Similarly, in current clinical practice,
preconception risk assessment is not offered systematically, but
most commonly offered opportunistically, for example when the
issue is brought up by the couple (Heyes 2004).
How the intervention might work
In the specified autosomal recessive disorders (thalassaemia, sickle
cell disease, cystic fibrosis and Tay-Sachs disease), preconception
genetic risk assessment ensures at-risk couples, in which both the
women and her partner are carriers of the specified conditions,
are aware that they have a one in four chance of an affected child
prior to pregnancy, enabling them to make fully informed repro-
ductive choices (Christie 2009; Czeizel 2012; Lena-Russo 2002;
Massie 2009; Mitchell 1996). This offers the at-risk couples the
opportunity to consider the full range of reproductive options
(Borry 2011); for instance, couples may choose to have in vitro
fertilisation (IVF) with pre-implantation genetic diagnosis, use
donor gametes, adopt a child or remain childless (HumanGenetics
Commission 2011; Jones 2002; Wille 2004). These options are
not available to couples who are only made aware of their repro-
ductive genetic risk during the pregnancy. Of equal importance,
if couples who have already been informed of their risk, decide to
carry on with pregnancy theymay consider and be offered prenatal
diagnosis earlier in pregnancy. This enables the option of termina-
tion in early gestation, or can enhance preparation for foetal and
maternal well-being throughout pregnancy, preparation following
the birth of an infant, and postnatal support. (Wille 2004). If the
carrier testing is implemented in the antenatal period, all of these
decisions are delayed (Qureshi 2004). With regards to family his-
tory assessment, participants have acknowledged that this inter-
vention enables pregnancy planning (Rose 1999) and early iden-
tification of couples at reproductive genetic risk (Czeizel 2012).
At a societal level, preconception carrier state identification has
reduced the rate of affected births (Angastiniotis 1998; Samavat
2004). Although, it is estimated that preconception screening pro-
grammes worldwide have caused a small decrease in affected births
for haemoglobin disorders from 2.7 per 1000 conceptions to 2.55
per 1000 conceptions over a five-year period from 1998 to 2003,
more data and across all common autosomal recessive conditions
need to be explored (Modell 2008). Similarly, early observational
studies involving genetic carrier screening programmes for Tay-
Sachs disease and thalassaemia in Canada and France carried out
in high school students were associated with increased rate of
early prenatal diagnosis and termination of affected pregnancies
(Lena-Russo 2002;Mitchell 1996; Zeesman 1984). InCyprus and
Iran, the incidence of thalassaemia has fallenwith the introduction
of mandatory pre-marital genetic carrier screening programmes
(Alswaidi 2009; Angastiniotis 1998; Samavat 2004). In Hungary,
preconception screening has resulted in improved identification of
carrier couples and access to genetic counselling services (Czeizel
2012). However, such observational studies are subject to bias.
Why it is important to do this review
While a number of observational studies have reported the po-
tential benefits of preconception risk assessment for genetic con-
ditions in general (Czeizel 2012), and specifically for cystic fi-
brosis (Christie 2009; Massie 2009), haemoglobinopathies (Cao
1996) and Tay-Sachs disease (Mitchell 1996), as with other pro-
grammes for genetic testing or screening, this has potential adverse
effects. Genetic assessment for reproductive risk has been linked
to psychological distress such as anxiety; however, the raised anxi-
ety was a transient phenomenon (Archibald 2011; Bekker 1994).
Further, it has been reported that carrier status may be associated
with a poor perception of health (Henneman 2001) and may have
an impact on the carrier’s relationships with their partner (Fanos
1995). Social impacts such as stigmatisation and discrimination
have been reported with mandatory carrier screening (Bonham
2010; Kenen 1978; Whitten 1973). Despite these reported ad-
verse effects, there are numerous psychological benefits including
the opportunity for informed decision-making and reproductive
autonomy in prospective parents (Anido 2005; Archibald 2011;
Lewis 2011).
With regards to the economic implications, as for other pro-
grammes for genetic testing and screening, there is an opportunity
cost for redistributing resources from medical care to preconcep-
tion risk assessment (WHO 1968). Several economic appraisals
of haemoglobinopathies screening in the antenatal and neona-
tal settings have indicated that these strategies are cost-effective
(Davies 2000; Zeuner 1999). A recent review of existing screening
programmes in Australia has shown that targeted preconception
screening in certain ethnic groups demonstrates both clinical and
cost-effectiveness (Lew 2014).
At a policy level, preconception genetic risk assessment has been
recommended in clinical practice in the Netherlands, the United
States of America and the United Kingdom (ACOG Committee
Opinion 2009; Health Council of Netherlands 2007; Human
Genetics Commission 2011). However, a comprehensive review
of the current evidence still needs to be undertaken to directly
inform healthcare practice.
This review will explore if robust trial evidence exists on the effect
of preconception genetic risk assessment for genetic disorders, par-
ticularly before its widespread routine implementation in current
healthcare settings.
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O B J E C T I V E S
The purpose of this review is to assess the effectiveness of system-
atic preconception genetic risk assessment to improve reproduc-
tive outcomes in women and their partners who are identified as
carriers of thalassaemia, sickle cell disease, cystic fibrosis or Tay-
Sachs disease in healthcare settings, when compared to usual care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned for this review to include all relevant randomised
controlled trials (RCTs) and quasi-randomised controlled trials
(quasi-RCTs).
Types of participants
Women and their partners of reproductive age (aged 16 to 50 years
old) who are carriers for thalassaemia, sickle cell disease, cystic fi-
brosis or Tay-Sachs disease, accessing any healthcare services which
include hospitals and community-based healthcare settings. Com-
munity-based healthcare settings include family or general prac-
tices, community health centres, community health services, com-
munity or outpatient clinics and ambulatory care services. Settings
outside of healthcare do not directly inform healthcare practice,
and thus will be excluded as being outside the scope of this review.
If trials contain both eligible and ineligible participants, they will
be included if data on eligible participants can be extracted.
Types of interventions
We planned to assess the effects of systematic preconception ge-
netic risk assessment for thalassaemia, sickle cell disease, cystic fi-
brosis or Tay-Sachs disease, in any healthcare setting. We define
systematic preconception genetic risk assessment as a package of
risk assessment including one or more of these components:
• family history assessment;
• assessment of ethnicity background;
• genetic carrier testing;
• genetic carrier screening.
Risk assessment can be offered at anytime prior to conception.
We planned to compare systematic preconception genetic risk as-
sessment with standard care. We define standard care as where
people receive usual or alternative care in any healthcare setting,
that does not involve a specific systematic approach to preconcep-
tion genetic risk assessment.
Types of outcome measures
The listed outcomes do not form part of the eligibility criteria for
the included trials.
Primary outcomes
1. Reproductive outcomes in women and their partners who
are carriers of thalassaemia, sickle cell disease, cystic fibrosis or
Tay-Sachs disease identified during or after pregnancy
i) number of infants born with genetic conditions
ii) number of infants born with congenital anomalies
iii) number of infants born with low birth weight
iv) number of infants born prematurely
2. Decisions about future conception and pregnancy in
women and their partners who are carriers for thalassaemia,
sickle cell disease, cystic fibrosis or Tay-Sachs disease
i) number of women or couples who would make use of
prenatal diagnosis
ii) number of women or couples who would make use of
prenatal diagnosis and consider termination of pregnancy if the
child is affected
iii) number of women or couples who would consider
pre-implantation genetic diagnosis and in vitro fertilization
iv) number of women or couples who would conceive
using donated gametes
v) number of women or couples who would consider
adoption
vi) number of women or couples who would refrain from
having any children
Secondary outcomes
1. During pregnancy following intervention
i) gestational date of prenatal diagnosis in at-risk women
ii) gestational date of prenatal counselling in at-risk
women or couples
2. Self-reported measures (short-term change from baseline)
i) any objective measures of health-related quality of life
resulting from preconception genetic risk assessment, using
validated tools such as Short Form Health Survey 36 (SF36) and
Health Questionnaire EQ-5D
ii) any objective measures of quantifying psychological or
social outcomes or both resulting from preconception genetic risk
assessment using validated tools such as Spielberger State-Trait
Anxiety Inventory (STAI), Perceived Stress Questionnaire (PSQ)
iii) knowledge (any measures of the women’s or couples’
or both, knowledge of reproductive genetic risk associated with
carrier status for thalassaemia, sickle cell disease, cystic fibrosis or
Tay-Sachs disease using validated self-reported questionnaire)
iv) satisfaction (any measures of the women’s or couples’
or both, satisfaction with the intervention using validated self-
reported questionnaire)
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3. Cost of the intervention (including follow-up visits and
tests)
Search methods for identification of studies
We did not apply language restrictions in the electronic searches.
If we identify potentially eligible non-English language trials in
future searches, we will source a person who can read the language
in order to assess these trials for possible inclusion and data ex-
traction.
Electronic searches
We sought trials from the relevant Cystic Fibrosis and Genetic
Disorders Group’s Trials Registers using the terms: (carrier* OR
trait OR risk assessment OR Tay-Sachs)) AND ((cystic fibro-
sis OR haemoglobinopathies OR Tay-Sachs). For full details of
all searching activities for the registers, please see the relevant
section of the Cochrane Cystic Fibrosis and Genetic Disorders
Group Module.
Date of latest search: 25 June 2015.
In addition, we searched all relevant trials from the following
databases:
1. Ovid MEDLINE (1970 until 10 December 2014);
2. Ovid Embase ((1974 until 10 December 2014);
3. CINAHL (1970 until 10 December 2014);
4. Ovid PsycINFO (1970 until 10 December 2014).
The search strategies are available in the appendices (Appendix 2;
Appendix 3; Appendix 4; Appendix 5). Start dates for database
searches are set to when carrier screening or testing was first avail-
able. Based onWHO reports, earliest carrier status assessment was
introduced for Tay-Sachs disease and haemoglobinopathies from
the early 1970s (Angastiniotis 1995; Kaback 2000). We searched
for relevant trials in the databases from 1970 or from when the
date of the database was first available if after 1970.
We searched the following clinical trial databases for ongoing and
unpublished trials:
• National Institutes of Health database;
• Clinical Trials Search Portal of the World Health
Organization;
• Current Controlled Trials in the metaRegister of
controlled clinical trials
Searching other resources
We planned to examine the reference lists of eligible published
trials to identify further relevant trials. We hand searched the key
journals European Journal of Human Genetics, Genetics in Medicine
and the Journal of Community Genetics from 1998 to 06 January
2014. We complemented the search by contacting subject experts
or centres in the field to request any unpublished or other pub-
lished trials that we may not have identified.
Data collection and analysis
Selection of studies
We saved the results of the searches in the Endnote reference man-
aging software (EndNote X3). Two review authors (one content
expert and one methodologist) independently screened the cita-
tions and article abstracts of every retrieved record.Wewould have
resolved any disagreements on eligibility by discussion and if doubt
remained, we would have acquired the relevant full article(s) for
further inspection. Two review authors independently screened
all full text articles of the eligible trials. We aimed to resolve any
disagreement by discussion. If required, we would have consulted
a third review author. If necessary, we planned to contact the au-
thors of the articles for further information and clarification of
trials. We have reported reasons for excluding trials and provided
a PRISMA flowchart (Figure 1).
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Figure 1. Study flow diagram
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We did not identify any trials for inclusion in this version of the
review. However, if we identify any trials for future updates of the
review, we plan to undertake the following.
Data extraction and management
Two review authors will independently extract data from each in-
cluded trial using an agreed data extraction form. We will collect
data on trial population characteristics (including sample size, par-
ticipants’ ethnic or cultural characteristics, geographic locations),
intervention characteristics (including process and duration of in-
tervention) and primary and secondary outcome measures of in-
terest. We plan to report short-term outcomes post intervention
up to six months. We plan to report long-term outcomes post in-
tervention from six months up to 12 months, and then annually
thereafter.
We will settle any disagreements about the data extracted through
discussion by the two review authors, and if necessary by arbitra-
tion with a third author. We will enter all the data into the Review
Manager software (RevMan 2014).
Assessment of risk of bias in included studies
We will construct a risk of bias table for each trial as outlined
in chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).
Two review authors will independently assess and record the fol-
lowing six domains in the risk of bias table:
1. random sequence generation;
2. allocation sequence concealment;
3. blinding of participants, trial personnel, outcome assessors;
4. incomplete outcome data;
5. selective outcome reporting;
6. other sources of bias.
We will judge the methods used in the trials for each domain as
having either a low, high or unclear risk of bias. Two review authors
will aim to resolve any disagreements in the judgement of the
domains through discussion. If no agreement can be reached, then
theywill consult a third author and aim to resolve the disagreement
by consensus.
Wewill record the information in the ’Risk of bias’ tables inReview
Manager (RevMan 2014). We aim to resolve any disagreement by
consensus or arbitration by a third author. We will use the results
of the risk of bias assessment to provide an evaluation of the overall
risk of bias of the included trials based on the approach outlined in
the chapter 8 (Table 8.7a) of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
Measures of treatment effect
We will extract all the main results of the included trials as men-
tioned below. We will contact relevant authors of the original re-
ports for data or any missing relevant information or when clarifi-
cation is needed. We will settle any disagreements about the data
extracted through discussion and if necessary by arbitration by a
third author. We will enter all the data into the Review Manager
software (RevMan 2014).
Continuous data
For scale-derived data, wewill include continuous data from rating
scales only if the measuring instrument has been validated. We
will include endpoint data and only use change data if the former
are not available. For continuous outcomes we will record mean,
standard deviation (SD) andnumber of participants for each group
and report effect size using themean difference (MD) for the same
units of measurement or the standardised mean difference (SMD)
when different scales are used to evaluate the same outcome, with
95% confidence intervals (CI). The MD measures the absolute
difference between the means in two groups, whereas the SMD is
the MD relative to variability observed in that trial.
Dichotomous data
We will report dichotomous data using the risk ratio (RR) and the
corresponding 95% CIs.
Unit of analysis issues
We anticipate cluster-randomised designs to be used in the in-
cluded trials; for example, groups of patients of a single doctor
or practice. If available, we will extract the direct estimate of the
effect (RR with CI) that accounts for a cluster design. We will
contact the primary authors of the included trials to obtain the
intra-cluster correlation coefficient (ICC) which will describe the
relative variability within and between clusters, to adjust for clus-
tering effect (Donner 1980). We will meta-analyse the appropri-
ate analyses of cluster randomised trials using the generic inverse
variance method. Alternatively, we will estimate an ICC to de-
scribe the relative variability within and between clusters (Donner
1980). An ICC usually derives from the trial or from other sources
(ICC from a similar trial in an existing database) (Ukoumunne
1999). If the ICC is derived from other sources, we will report
this and conduct a sensitivity analysis. If the trials were analysed
as if the randomisation was performed on the individuals rather
than the clusters, we will re-calculate the correct analysis if we are
able to extract the following information: the number of clusters
randomised to each intervention group; themean size of each clus-
ter; and the outcome data ignoring the cluster design for the total
number of individuals.
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If we identify more than one intervention group of interest in a
trial, we will analyse the effect of the additional intervention group
using pair-wise comparisons. If the additional intervention group
is irrelevant, we will not reproduce the data.
Dealing with missing data
Whenever possible, we will contact the original investigators and
the authors of the included trials to request any missing data. If
this is unsuccessful we will deal with missing data as mentioned
below.
Overall loss of credibility
We will choose that, if for any particular outcome there is a high
risk bias for missing data according to the risk of bias assessment,
we will not use these data in the analyses and will present the
results in the form of a narrative synthesis.
Continuous data
If SDs are not reported or available, we will first look for statistics
that allow the calculation of the SD (for example, the CI and the
standard error (SE) of group means, as well as P values and T
values for the differences in means). If this is not possible, we will
consider imputing SDs of other included trials. We will examine
the consequences of imputations in a sensitivity analysis.
Assessment of heterogeneity
Clinical heterogeneity
We will consider clinical heterogeneity which can result from dif-
ferences between trials in characteristics of the populations, in-
terventions and outcomes. We will fully discuss the influence of
clinical heterogeneity on the observed effects.
Methodological heterogeneity
We will assess for methodological heterogeneity, which can result
from differences in characteristics of the trial designs. We will
fully discuss the influence of methodological heterogeneity on the
observed effects.
Statistical heterogeneity
Weplan to examine graphs or summary tables of the trials to inves-
tigate the possibility of statistical heterogeneity. We plan to con-
sider the I2 statistic which estimates the proportion of variability
in effect estimates that is due to heterogeneity (Higgins 2002).We
will determine the level of heterogeneity by the following reference
ranges: low 0% to 40%; moderate 41% to 75%; and high 76% to
100%. We also plan to use the Chi2 statistic and if the P value is
less than 0.10 it will be considered an indication of heterogeneity.
If there is a high level of heterogeneity between trials, it may not
be appropriate to conduct a meta-analysis, thus we will present
results in a qualitative analysis. These trials will be entered into
RevMan and presented on a forest plot with their individual effect
sizes, but with no combined effect to give an overall picture of
evidence (RevMan 2014).
Assessment of reporting biases
If the review includes more than 10 trials, we will create a funnel
plot to investigate the possibility of small trial effects (a tendency
for the intervention effects estimated in smaller trials to differ from
those estimated in larger trials) (Sterne 2011).
Data synthesis
We will summarise all trials using narrative synthesis methods.
This will involve the use of narrative text and tables to summarise
data, consider outcomes in the light of differences in trial designs
and address potential sources of bias for each of the trials being
reviewed. We will group trials according to types of genetic con-
ditions, and then organise them in terms of intervention and out-
comes. We will summarise the results of the trials, including the
range and size of any reported associations and important trial
characteristics. We will also include a detailed commentary on the
major methodological problems or biases affecting the trials, to-
gether with a description of how these may have affected the in-
dividual trial results.
We will use a random-effects model to conduct the meta-analysis
due to anticipated differences between trial location and popula-
tion. If there is substantial variation in results, particularly if there
is inconsistency in the direction of effect, we will not perform a
meta-analysis.
Subgroup analysis and investigation of heterogeneity
The authors will perform subgroup analyses where sufficient data
are available. In the subgroup analyses, the authors will analyse the
data in pre-specified subgroups of trials that share characteristics of
interest, to see whether the intervention effect remains consistent
or whether it varies for particular characteristics of trials. For this
review, the authors aim to compare the effects of interventions on
outcome measures in the following groups by:
• healthcare setting (primary, secondary, tertiary care or
other);
• intensity of the intervention (number or duration of
intervention sessions);
• nature of carrier status testing (confirmed genetic carrier
status compared to probable carrier status);
• type of condition.
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Sensitivity analysis
If there is a spread of bias across the trials, we will provide two
estimates of the intervention effect; firstly for all included trials,
and secondly only including trials with an overall assessment of a
low risk of bias.
R E S U L T S
Description of studies
Results of the search
Database searching identified 4207 records. After screening 2695
unique records, 22 full-text articles describing 14 unique trials
were retrieved for further analysis. No RCTs were found that were
eligible for inclusion in the review. A flow diagram illustrates the
search flow process (Figure 1).
Included studies
No RCTs were found to be eligible for inclusion in the review.
Excluded studies
Ten studies were excluded due to non-RCT study designs
(Alhamdan 2007; Bekker 1993; Childs 1976; Clayton 1996;
Hegwer 2006; Henneman 2001; Honnor 2000; Payne 1997;
Tambor 1994; Watson 1991), while four RCTs were excluded be-
cause the intervention was not preconception genetic carrier test-
ing or genetic carrier screening (Castellani 2011; Cheuvront 1998;
Fisher 1981; Wilkie 2013). The table Characteristics of excluded
studies summarises the study details and reasons for exclusions.
Risk of bias in included studies
No trials were included in this review.
Effects of interventions
No trials were eligible for inclusion in this review.
D I S C U S S I O N
Summary of main results
Identifying those couples before pregnancy, who have a confirmed
genetic carrier status for thalassaemia, sickle cell disease, cystic fi-
brosis, or Tay-Sachs disease may provide the opportunity for in-
dividuals or couples to make fully informed reproductive choices
such as avoiding pregnancy, pre-implantation diagnosis, in vitro
fertilisation, arranging early prenatal diagnosis, or consideration
of adoption. However, there is currently no evidence from ran-
domised controlled trials (RCTs) for the impact of genetic risk
assessment for these conditions in non-pregnant women on preg-
nancy outcomes, informed reproductive choices or psychological
adverse effects.
Overall completeness and applicability of
evidence
To date, in many countries, reproductive genetic risk assessment
for autosomal recessive disorders has focused on the antenatal pe-
riod and carrier status that has emerged as an incidental finding in
neonatal screening. In the antenatal period, carrier status is identi-
fied either through formal screening programmes, or opportunis-
tically during antenatal follow up in women at increased risk based
on ancestry. During the antenatal period, if both parents are found
to be carriers of the genes (at-risk couples), prenatal diagnostic
tests, such amniocentesis, may only be available either late in the
first trimester or in the second trimester of pregnancy, which leaves
the couple only a short period of time to make limited and diffi-
cult choices about termination or continuation of the pregnancy.
This limits reproductive choices, with the potential of increased
psychological distress in at-risk couples (Modell 1980a; Modell
1980b). The incidental finding of the carrier state during neonatal
screening for the specific disorders has highlighted concerns from
at-risk couples about the failure to offer this information prior to
pregnancy (Locock 2008).
The evidence supporting genetic risk assessment before pregnancy
has largely been from a series of observational studies (Alhamdan
2007; Bekker 1993; Childs 1976; Clayton 1996; Hegwer 2006;
Henneman 2001; Honnor 2000; Payne 1997; Tambor 1994;
Watson 1991). Themajority of the observational studies have used
before and after intervention designs (Bekker 1993; Clayton 1996;
Hegwer 2006; Henneman 2001; Honnor 2000; Payne 1997;
Tambor 1994; Watson 1991), while two studies utilised cross-sec-
tional designs (Alhamdan 2007; Childs 1976). Four RCTs were
also identified (Castellani 2011; Cheuvront 1998; Fisher 1981;
Wilkie 2013). However, the intervention in these studies was not
preconception genetic risk assessment. Only a few studies have
assessed reproductive intentions (Cheuvront 1998; Henneman
2001; Watson 1991), whilst no studies have assessed actual repro-
ductive outcomes. The limited duration of follow up in these stud-
ies would make assessment of latter outcomes unrealistic. All of
the above studies have assessed psychological, attitudes, or knowl-
edge outcomes, but there was some heterogeneity in these out-
comes between and within studies. Further, none of the outcome
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measures for knowledge had used validated instruments. Although
study participants recognised the importance of identifying ge-
netic carrier states before pregnancy, different attitudes towards
genetic testingwere elicited and reproductive intentions varied fol-
lowing positive test results. In the Netherlands, study participants
would consider prenatal diagnosis and abortion if an affected foe-
tus is identified (Henneman 2001). In contrast, in the US state of
Tennessee in a study of cystic fibrosis screening, reproductive in-
tentions were limited by cultural and socio-political factors, such
as, insurability, being labelled as ’at risk’, a lack of understanding,
and religious beliefs about abortion (Clayton 1996). In addition,
barriers to implementation may be due to fears of stigma (Kenen
1978), legal discrimination (Lapham 1996), or religious restric-
tions on abortion (Fowzan 2001).
Despite the absence of robust and relevant RCT evidence, a num-
ber of international organisations have recommended offering
preconception genetic risk assessment routinely at the popula-
tion level (ACOGCommittee Opinion 2005; ACOGCommittee
Opinion 2009; Health Council of Netherlands 2007; Human
Genetics Commission 2011; Johnson 2006). In the United States
of America, the recommendations to improve preconception
health care were developed through collaborative efforts of the
Centres for Disease Control and Prevention (CDC), March of
Dimes and the American College of Obstetrics and Gynaecol-
ogy (ACOG) (ACOGCommittee Opinion 2005; Johnson 2006).
For instance, the ACOG has recommended in couples planning
pregnancy identify if either member of the couple are of Eastern
European (Ashkenazi) Jewish ancestry or have a family history of
relevant recessive genetic diseases (such as Tay-Sachs disease and
Cystic Fibrosis), and such couples should be offered carrier screen-
ing before conception or early in pregnancy (ACOG Committee
Opinion 2009).
Similarly the Health Council of Netherlands has recognised the
seriousness of these conditions and high prevalence in local pop-
ulation groups, advocating preconception genetic risk assessment
for cystic fibrosis, sickle cell and thalassaemia (Health Council of
Netherlands 2007). However, the paucity of high quality studies
limits the justification for national implementation.
The WHO’s Regional Office of Eastern Mediterranean recom-
mend preconception genetic risk assessment for sickle cell and
thalassaemia ideally before marriage, taking account of the socio-
cultural issues in the region, in particular religious reservations to-
wards termination of pregnancy (Alwan 1997). Since the 1970s,
theCyprus Thalassaemia Control Programme has been at the fore-
front of premarital genetic screening and this has contributed to a
fall in the prevalence of thalassaemia in the country (Angastiniotis
1981). This universal premarital approach to thalassaemia carrier
screening has also been adopted by Sardinia, Italy (Cao 1996) and
Greece (Loukopoulos 1996).
In line with international policy recommendations, the UK Hu-
man Genetics Commission has recognised that since antenatal
screening is currently already offered for genetic conditions such
as sickle cell disease and thalassaemia, there are no ethical, legal or
social issues with regards to the implementation of a preconcep-
tion screening programme which would provide the advantage of
improving reproductive choices (Human Genetics Commission
2011).
In South East Asia, the Family PlanningAssociation ofHongKong
has recognised the benefits of preconception screening of genetic
risk due to the high prevalence of thalassaemia carriers, accounting
for up to eight per cent of the local population (Lau 1997).
In the absence of high quality randomised controlled trials of pre-
conception genetic risk assessment, as demonstrated in this sys-
tematic review, international policy makers must base recommen-
dations on observational studies and consensus agreements.
Quality of the evidence
It has been suggested that the optimum evidence to evaluate the
reproductive and psychological outcomes as a result of precon-
ception screening, compared to standard practice, is a system-
atic review of RCTs, or a high quality RCT with a large enough
sample size to ensure the control of potential confounding fac-
tors (National Screening Committee 2003). Such trials address
methodological issues that are particularly associated with screen-
ing interventions such as ascertainment bias due to non-randomi-
sation, with individuals joining screening programmes tending
to have healthier lifestyles and better adherence to interventions
(Smith 2003). In addition, none of the excluded studies identified
in the searches for this review have evaluated reproductive out-
comes. This is possibly related to the limited duration of follow up
in these studies. Although preconception genetic carrier tests and
screening have been shown to be to highly accurate and efficient in
determining carrier status (Bach 2001; CDC 2004; Peters 2012;
Weatherall 1997), the effectiveness of such interventions is ulti-
mately measured by their ability to reduce morbidity and mortal-
ity of the diseases. Therefore, reproductive outcomes are essential
to addressing this question.
Since this systematic review shows that there is a complete lack
of RCTs in the field of preconception genetic risk assessment for
autosomal recessive conditions, healthcare providers need to as-
sess whether the information provided in published policy rec-
ommendations and non-randomised studies is relevant to inform
their preconception screening practice. Furthermore, healthcare
providers have to balance the benefits of increasing reproductive
choice against the potential psychological adverse effects from pre-
conception genetic risk assessment, whilst taking into account the
legal and socio-cultural context of their healthcare setting and pa-
tient population.
Potential biases in the review process
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The review authors have attempted to limit the bias in the re-
view process through multiple authors and non-author contrib-
utors who independently searched for trials, screened titles and
abstracts, selected full-text articles and extracted data. Any dis-
agreements were resolved by group discussion and consensus, and
therefore it was unlikely that trials have been incorrectly excluded.
Although all clinical trials should be registered, there is always the
potential of publication bias. However, attempts have been made
to minimise publication bias through searching the grey literature
and contacting key experts in the field.
Agreements and disagreements with other
studies or reviews
This is the only systematic review looking at preconception genetic
risk assessment for thalassaemia, sickle cell disease, cystic fibrosis
and Tay-Sachs disease and there were no randomised controlled
trials eligible for inclusion, and therefore no comparisons could
be made to other reviews or studies.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
No RCTs of preconception genetic risk assessment for thalas-
saemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease were
found for inclusion in this review. Therefore, the research evidence
on which to base clinical decisions is limited to non-randomised
studies, which have largely formed the basis for current policy rec-
ommendations.
We have not identified any relevant trials up tomost current search
date 10 December 2014.
Implications for research
Previous observational studies andRCTs on preconception genetic
risk assessment for thalassaemia, sickle cell disease, cystic fibrosis,
or Tay-Sachs disease have been limited by duration of follow up
and to assessment of psychological or knowledge outcomes. Ade-
quately-powered RCTs assessing reproductive outcomes (number
of affected children born with genetic conditions) and reproduc-
tive decision outcomes on future conception (termination, in vitro
fertilisation, use of donor gametes, adoption, or refraining from
having children) are needed to better inform recommendations for
clinical practice. Any self-reported secondary outcome measures
need to use validated instruments. These trials will require longer
durations of follow up than previous studies, starting from pre-
pregnancy and lasting into the post-natal period. In the future,
rather than offering genetic testing for specific autosomal-reces-
sive conditions, genomic technology, such as pan-ethnic massively
parallel sequencing (Bell 2011), may be adopted in which a panel
of genetic conditions is identified. However, such trials must also
consider the legal, ethical, and cultural barriers to implementation
of preconception genetic risk assessment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alhamdan 2007 Participants: couples planning to marry and applying for marriage licence
Intervention: premartial screening programme for sickle cell and beta-thalassemia
Comparator: none
Outcome: number confirmed sickle cell and beta thalassemia carriers, decision for marriage
Design: observational, cross-sectional study
Excluded due to non-RCT design
Bekker 1993 Participants: adults 18 - 45 years
Intervention: genetic carrier testing for cystic fibrosis
Comparator: none
Outcome: anxiety
Design: observational, before and after intervention study
Excluded due to non-RCT study design
Castellani 2011 Participants: infertile couples undergoing cystic fibrosis screening as part of assisted reproduction process
Intervention: genetic counselling via computer program
Comparator: standard care genetic counselling session
Outcome: knowledge
Design: RCT
Excluded because intervention was method of delivering genetic counselling and not preconception genetic carrier
testing or screening compared to standard care
Cheuvront 1998 Participants: relatives of people with cystic fibrosis
Intervention: home-based pretest education from pamphlet with genetic test
Comparator: clinic based pretest education via genetic counselling with genetic test
Outcome: anxiety, knowledge, satisfaction, reproductive intent
Design: RCT
Excluded because intervention was method of delivering genetic counselling and not preconception genetic carrier
testing or screening compared to standard care
Childs 1976 Participants: carriers of Tay-Sachs disease identified prospectively or retrospectively during population screening
Intervention: genetic carrier population screening
Comparator: none
Outcomes: knowledge, attitudes, anxiety, concerns, satisfaction
Design: observational, cross-sectional
Excluded due to non-RCT study design
Clayton 1996 Participants: non-pregnant adults visiting clinical and non-clinical sites
Intervention: genetic carrier testing for cystic fibrosis
Comparator: none
Outcome: attitudes, beliefs
Design: observational, before and after intervention design
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(Continued)
Excluded due to non-RCT study design
Fisher 1981 Participants: adults carriers of beta-thalassaemia 18 - 65 years in a HMO
Intervention: genetic counselling through video
Comparator: conventional counselling by trained physician
Outcome: knowledge, sexual activity, mood change, behaviour, anxiety
Design: RCT
Excluded because intervention is not preconception genetic carrier testing or screening
Hegwer 2006 Participants: adults of Ashkenazi Jewish background in prenatal and preconception settings
Intervention: genetic carrier screening and education programme for Tay-Sachs disease
Comparator: none
Outcome: knowledge, concern, attitudes, perceptions of genetic risk
Design: observational, before and after intervention
Excluded due to non-RCT study design
Henneman 2001 Participants: adults aged 20 - 35 years invited through Municipal Health Service or General Practitioner
Intervention: genetic carrier screening for cystic fibrosis
Comparator: none
Outcome: knowledge, attitudes, understanding, satisfaction, psychological well-being, uptake, worry, reproduc-
tive intentions, sharing of information
Design: observational, before and after intervention
Excluded due to non-RCT study design
Honnor 2000 Participants: adults 18 - 50 years in a primary care setting
Intervention: genetic carrier testing and counselling for cystic fibrosis
Comparator: none
Outcome: anxiety, knowledge
Design: observational, before and after intervention
Excluded due to non-RCT study design
Payne 1997 Participants: adults 16 - 45 years in one primary care practice in South Wales
Intervention: genetic carrier testing for cystic fibrosis
Comparator: none
Outcome: knowledge, anxiety
Design: observational, before and after intervention
Excluded due to non-RCT study design
Tambor 1994 Participants: adults 18 - 44 years in a HMO
Intervention: invitation offering cystic fibrosis carrier screening and information giving either by personal edu-
cation on-site or by mailed brochure
Comparator: none
Outcome: attitudes, tolerance, utilization
Design: observational, before and after intervention
Excluded due to non-RCT study design
Watson 1991 Participants: adults 16 - 44 years from primary care practices and family planning clinics
Intervention: genetic carrier testing for cystic fibrosis
Comparator: none
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(Continued)
Outcome: anxiety, response to positive results, knowledge, reproductive intentions, behaviour
Design: observational, before and after intervention
Excluded due to non-RCT study design
Wilkie 2013 Participants: adults 18 - 35 years with sickle cell disease or sickle cell trait from clinics and community settings
Intervention: web-based multimedia educational intervention
Comparator: usual care information e-book
Outcome: knowledge, reproductive intent and behaviour
Design: randomised controlled trial
Excluded because intervention was the delivery of education and not preconception genetic carrier testing or
screening
HMO: health maintenance organisation
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Glossary
Term Explanation
Antenatal A period during pregnancy and before birth of the child.
Ancestry A person’s ethnic origin or descent.
Atelectasis A collapsed portion of the lung which does not contain air. This can
be caused by excessive accumulations of mucous secretions, inhaled
foreign bodies or bronchial cancers
Autosomal recessive genetic disorders A genetic trait or disorder which appears only when an individual
inherits a pair of chromosomes, each containing the gene for the
trait. One chromosome of the pair comes from the father and the
other from themother. Autosomal recessive disorders can occur only
if both parents are carriers of the trait
Bronchiectasis Persistent and progressive dilation of bronchi (branches from the
trachea which lead to the lungs) often as a consequence of inflam-
matory disease (lung infections)
Carrier (in genetics) An individual who possesses one copy of a mutated allele that causes
disease only when two copies are present (an autosomal recessive
genetic disorders). A carrier is not affected by the disease, but two
carriers can produce a child with the disease
Chronic vaso-occlusion Blockage of arteriesmarkedby longduration, by frequent recurrence
over a long time, and often by slowly progressing deterioration;
having a slow progressive course of indefinite duration
Cystic fibrosis transmembrane conductance regulator (CFTR) A protein, involved in the movement of salt across cell membranes,
which is lacking or does not function normally in people with cystic
fibrosis
Diabetes mellitus A pancreatic disorder that causes abnormal insulin production. This
affects the body’s ability to utilise sugar and other food substances
and is usually treated by diet modification (restricted sugar intake)
and use of insulin
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(Continued)
DNA (Deoxyribonucleic acid) The chemical coding for a gene. DNA determines the ’genetic mes-
sage’ within each cell, organ, and organism
Electrophoresis A method of separating particles relative to a fluid under the influ-
ence of a spatially uniform electric field
Ethnicity Common characteristics of people of a distinct national, racial or
cultural group
Gangliosides A group of glysolipid cells that are found in the brain.
Gene The functional and physical unit of heredity passed from parent to
offspring. Genes are pieces of DNA, and most genes contain the
information for making a specific protein
Globin chains Blood proteins found in red blood cells that are combined to make
haemoglobin. They are α or β globin chains
Haemoglobin A Normal adult haemoglobin.
Haemoglobin F A kind of haemoglobin usually present during fetal (intrauterine)
life, which has a different chemical structure from normal adult
haemoglobin. After birth, the fetal haemoglobin in the red blood
cells is gradually replaced by the adult type of haemoglobin, this
process is usually complete during the first six months of life
Haemolysis Breaking of the red cell membrane causing release of haemoglobin
Haemolytic anaemia A condition where there are fewer red blood cells than average circu-
lating in the blood stream due to breaking of the red cell membrane
causing release of haemoglobin
Hexosaminidase A isozyme A protein found in the nerve cells of the brain which does not
function normally in people with Tay-Sachs disease
High performance liquid chromatography (HPLC) Amethod that is used to separate amixture of compounds to identify
and quantify the individual components of the mixture
Hypothyroidism Results from a deficiency of thyroid hormone, and is characterized
by a decrease in basal metabolic rate and by tiredness, lethargy and
sensitivity to cold
In vitro fertilization A technique by which eggs are collected from a woman and fertilised
with a man’s sperm outside the body. Usually one or two resulting
embryos are then transferred to the womb. If one or more of them
implants successfully in the womb it results in a pregnancy
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(Continued)
In vivo Inside the living body.
Mutation A change or alteration of the DNA sequence within a gene.
Nasal epithelium The tissue that covers and lines the surface of the nose.
Obstructive azoospermia A condition where there is no measurable sperm detected in the
semen due to ejaculatory dysfunction or ductal blockage. This con-
dition can occur in people with cystic fibrosis
Pancreatic exocrine insufficiency A condition characterized by deficiency of the pancreatic enzymes,
resulting in the inability to digest food properly, or maldigestion
Salt-loss syndromes A condition found in people with cystic fibrosis where there is loss
of salt resulting in depletion of salt in the body
Septicaemia A condition characterized by the widespread destruction of tissues
due to absorption of disease containing bacteria or their toxins from
the bloodstream
For further statistical terms, please refer to the The Cochrane Collaboration Glossary (http://cochrane.org/glossary).
For technical or clinical terms, please refer to The Human Genetics Commission Glossary (http://webarchive.nationalarchives.gov.uk/
20100419143351/hgc.gov.uk/client/content.asp?contentid=729).
Appendix 2. MEDLINE search strategy (1970 to 10 December 2014)
Ovid MEDLINE(R) Daily Update
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R)
1. exp Thalassemia/
2. thalass?emia.ti,ab,ot,hw.
3. ((erythroblastic or erythro-blastic or hypochromic or cooley$ or mediterranean) adj2 an?emia$).ti,ab,ot,hw.
4. (h?emoglobin adj2 disease$).ti,ab,ot,hw.
5. exp Hemoglobinopathies/
6. hereditary persistence of f?etal h?emoglobin.ti,ab,ot,hw.
7. (h?emoglobin adj2 (H or F or D or E) adj2 disease$).ti,ab,ot,hw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Anemia, Sickle Cell/
10. Sickle Cell Disease.ti,ab,ot,hw.
11. (sickle cell adj2 (an?emia$ or disease$ or disorder$)).ti,ab,ot,hw.
12. (h?emoglobin adj2 (S or C or SC)).ti,ab,ot,hw.
13. ((drepanocytosis or drepanocytic) adj2 an?emia).ti,ab,ot,hw.





19. (fibrocystic adj3 disease$).ti,ab,ot,hw.
20. (pancreas$ adj2 (fibrosis or cystic disease$)).ti,ab,ot,hw.
21. 15 or 16 or 17 or 18 or 19 or 20
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22. Tay-Sachs Disease/
23. Tay Sachs.ti,ab,ot,hw.
24. ((familial or infantile) adj2 amaurotic idiocy).ti,ab,ot,hw.
25. TSD.ti,ab.
26. (GM2 adj2 gangliosidosis).ti,ab,ot,hw.




31. 28 or 29 or 30
32. 8 or 14 or 21 or 27 or 31
33. (Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$).ti,ab,ot,hw.
34. Maternal Health Services/
35. ((pregnan$ or conception or family) adj3 plan$).ti,ab,ot,hw.
36. (Pre-marital or Premarital or Pre-marriage or Premarriage).ti,ab,ot,hw.
37. ((Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.
38. ((Pre-marital or Premarital or Pre-marriage or Premarriage) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.
39. 33 or 34 or 35 or 36 or 37 or 38
40. (carrier$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.
41. (genetic$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.
42. (heterozygot$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.
43. Genetic Services/
44. family history.ti,ab,ot,hw.
45. 40 or 41 or 42 or 43 or 44
46. (h?emoglobin adj2 electrophoresis).ti,ab,ot,hw.
47. Cystic Fibrosis Transmembrane Conductance Regulator/ or sweat test.ti,ab,ot,hw.
48. ((CFTR gene mutation$ or CFTR mutation$ or Hexoaminidase-A or Hexoaminidase A or HEX-A or H?emoglobin F or H?
emoglobin A2 or H?emoglobin S) adj3 (test$ or analys$ or screen$ or profil$)).ti,ab,ot,hw.
49. 46 or 47 or 48
50. 32 or 45 or 49
51. 39 and 50
52. exp animals/ not humans.sh.
53. 51 not 52
54. limit 53 to yr=”1970-Current“
Appendix 3. PsycINFO search strategy (1970 to 10 December 2014)
1. thalassemia.ti,ab,ot,hw.
2. thalassaemia.ti,ab,ot,hw.
3. ((erythroblastic or erythro-blastic or hypochromic or cooley* or mediterranean) adj2 anaemia*).ti,ab,ot,hw.
4. ((erythroblastic or erythro-blastic or hypochromic or cooley* or mediterranean) adj2 anemia*).ti,ab,ot,hw.
5. ((haemoglobin or hemoglobin) adj2 disease*).ti,ab,ot,hw.
6. ((haemoglobin or hemoglobin) adj2 (H or F or D or E) adj2 disease*).ti,ab,ot,hw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Sickle Cell Disease/
9. (sickle cell adj2 (anaemia* or disease* or disorder*)).ti,ab,ot,hw.
10. ((haemoglobin or hemoglobin) adj2 (S or C or SC)).ti,ab,ot,hw.
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15. mucoviscidosis.ti,ab,ot,hw.
16. (fibrocystic adj3 disease*).ti,ab,ot,hw.
17. 12 or 13 or 14 or 15 or 16
18. Tay Sachs Disease/
19. Tay Sachs.ti,ab,ot,hw.
20. ((familial or infantile) adj2 amaurotic idiocy).ti,ab,ot,hw.
21. TSD.ti,ab.
22. (GM2 adj2 gangliosidosis).ti,ab,ot,hw.




27. 24 or 25 or 26
28. 7 or 11 or 17 or 23 or 27
29. (Preconcept* or Pre-concept* or Prepregnan* or Pre-pregnan*).ti,ab,ot,hw.
30. (Pre-marital or Premarital or Pre-marriage or Premarriage).ti,ab,ot,hw.
31. maternal health service*.ti,ab,ot,hw.
32. maternal care.ti,ab,ot,hw.
33. ((pregnan* or conception or family) adj3 plan*).ti,ab,ot,hw.
34. ((Preconcept* or Pre-concept* or Prepregnan* or Pre-pregnan*) adj2 (care or counsel* or advice* or advise or inform*)).ti,ab,ot,hw.
35. ((Pre-marital or Premarital or Pre-marriage or Premarriage) adj2 (care or counsel* or advice* or advise or inform*)).ti,ab,ot,hw.
36. 29 or 30 or 31 or 32 or 33 or 34 or 35
37. (genetic* adj3 (screen* or test* or counsel* or assess* or detect* or diagnos* or inform* or analys*)).ti,ab,ot,hw.
38. (carrier* adj3 (screen* or test* or counsel* or assess* or detect* or diagnos* or analys*)).ti,ab,ot,hw.
39. (heterozygot* adj3 (screen* or test* or counsel* or assess* or detect* or diagnos* or analys*)).ti,ab,ot,hw.
40. genetic service*.ti,ab,ot,hw.
41. family history.ti,ab,ot,hw.
42. 37 or 38 or 39 or 40 or 41
43. ((haemoglobin or hemoglobin) adj2 electrophoresis).mp. [mp=title, abstract, heading word, table of contents, key concepts, original
title, tests & measures]
44. Cystic Fibrosis Transmembrane Conductance Regulator/ or sweat test.mp.
45. 43 or 44
46. 28 or 42 or 45
47. 36 and 46
48. exp Animals/
49. human.mp.
50. 48 and 49
51. 48 not 50
52. 47 not 51
53. limit 52 to yr=”1970-Current“
Appendix 4. Embase search strategy (1974 to 06 January 2014)
1. exp thalassemia/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
2. exp delta thalassemia/ or exp beta thalassemia/ or exp thalassemia major/ or exp alpha thalassemia/ or exp thalassemia intermedia/
or exp sickle cell beta thalassemia/ or exp thalassemia minor/
3. thalass?emia.ti,ab,ot,hw.
4. ((erythroblastic or erythro-blastic or hypochromic) adj2 an?mia$).ti,ab,ot,hw.
5. (h?emoglobin adj2 disease$).ti,ab,ot,hw.
6. hemoglobinopathy/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
7. hereditary persistence of f?etal h?emoglobin.ti,ab,ot.
8. (h?emoglobin adj2 (h or d or e) adj2 disease$).ti,ab,ot,hw.
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9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp sickle cell anemia/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
11. sickle cell disease.ti,ab,ot,hw.
12. (h?emoglobin adj2 (s or c)).ti,ab,ot,hw.
13. 10 or 11 or 12
14. exp cystic fibrosis/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
15. cystic fibrosis.ti,ab,ot,hw.
16. CF.ti,ab.
17. 14 or 15 or 16
18. exp Tay Sachs disease/cn, di, ep, et, pc [Congenital Disorder, Diagnosis, Epidemiology, Etiology, Prevention]
19. Tay Sachs.ti,ab,ot,hw.
20. ((familial or infantile) adj2 amaurotic idiocy).ti,ab,ot,hw.
21. TSD.ti,ab.
22. 18 or 19 or 20 or 21
23. exp heterozygote/ or exp heterozygote detection/
24. trait$.ti,ab,ot,hw.
25. carrier$.ti,ab,ot,hw.
26. 23 or 24 or 25
27. 9 or 13 or 17 or 22 or 26
28. (Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$).ti,ab,ot,hw.
29. (Pre-marital or Premarital or Pre-marriage or Premarriage).ti,ab,ot,hw.
30. ((pregnan$ or conception or family) adj3 plan$).ti,ab,ot,hw.
31. ((Preconcept$ or Pre-concept$ or Prepregnan$ or Pre-pregnan$) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.
32. ((Pre-marital or Premarital or Pre-marriage or Premarriage) adj2 (care or counsel$ or advice$ or advise or inform$)).ti,ab,ot,hw.
33. 28 or 29 or 30 or 31 or 32
34. (carrier$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.
35. (genetic$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.
36. (heterozygot$ adj3 (screen$ or test$ or counsel$ or assess$ or detect$ or diagnos$ or inform$ or analys$)).ti,ab,ot,hw.
37. Genetic Service$.ti,ab,ot,hw.
38. family history.ti,ab.
39. 34 or 35 or 36 or 37 or 38
40. (h?emoglobin adj2 electrophoresis).ti,ab,ot,hw.
41. Cystic Fibrosis Transmembrane Conductance Regulator.ti,ab,ot,hw.
42. sweat test.ti,ab.
43. ((CFTR gene mutation$ or CFTR mutation$ or Hexoaminidase-A or Hexoaminidase A or HEX-A or H?emoglobin F or H?
emoglobin A2 or H?emoglobin S) adj3 (test$ or analys$ or screen$ or profil$)).ti,ab,ot,hw.
44. 40 or 41 or 42 or 43
45. 27 or 39 or 44
46. 33 and 45
47. animal/
48. human/
49. 47 and 48
50. 47 not 49
51. 46 not 50
52. limit 51 to yr=”1970-Current“
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Appendix 5. CINAHL search strategy (1970 to 10 December 2014)
SI. (MH ”Thalassemia“) OR (MH ”beta-Thalassemia“) OR (MH ”alpha-Thalassemia“) OR (MH ”delta-Thalassemia“)
S2. (MH ”Hemoglobinopathies“)
S3. (MM ”Anemia, Hypochromic“)
S4. (MH ”Anemia, Sickle Cell“) OR (MH ”Sickle Cell Trait“)
S5. (MH ”Cystic Fibrosis“) OR ”mucoviscidosis“
S6. (MH ”Tay-Sachs Disease“)
S7. (MH ”Prepregnancy Care“)
S8. (MH ”Genetic Screening“)
S9. (MH ”Family Assessment“) OR (MH ”Family History“)
S10. ”hemoglobin electrophoresis“
S11. ”cystic fibrosis transmembrane conductance regulator“
S12. ”sweat test“
S13. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S8 OR S9 OR S10 OR S11 OR S12
S14. S7 AND S13
S15. Limiters - Published Date from: 19700101-current
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